

Guidance to support implementation of Inclisiran within the lipid management pathway



Yorkshire
& Humber
AHSN

Background

In January 2020, NHS England and NHS Improvement partnered with Novartis Pharmaceuticals UK, to launch Inclisiran (Leqvio) in England to help tackle cardiovascular disease (CVD) in the first NHS population health agreement. The LTP sets out a major ambition to prevent 150,000 strokes, heart attacks and dementia cases over the next 10 years.

The Yorkshire & Humber Academic Health Science Network (AHSN) has been tasked to support the Integrated Care Systems (ICSs) to adopt Inclisiran across the region in line with [NICE guidance](#).

Inclisiran forms part of three interlinked national programmes which have been designed to provide a comprehensive approach to lipid management:

1. The Accelerated Access Collaborative Rapid Uptake Programme
2. The AHSN Network Lipid Management and Familial Hypercholesterolaemia (FH) Programme
3. Improved lipid management in England associated with the implementation of Inclisiran into the lipid management pathway

The Yorkshire & Humber AHSN has a long history of working in collaboration with our local systems to support patients and specifically working on CVD prevention through the West Yorkshire and Harrogate Healthy Hearts programme.

The purpose of this briefing is to provide some useful information to facilitate the adoption of Inclisiran including patient eligibility criteria, drug safety, funding, prescribing and how to get in touch with any enquiries.



Guidance to support implementation of Inclisiran within the lipid management pathway

Rationale for Inclisiran and the partnership with Novartis

The introduction of Inclisiran into the lipid management pathway addresses a current gap in the range of treatment options available for people with CVD, in whom lipid targets cannot be met on maximally tolerated statin treatment or with other lipid-lowering therapies such as Ezetemibe

The partnership with Novartis helps to build on the UK's Science and Research infrastructure, and will help harness the UK's unique genomic and health data and, in time, help the UK position itself and the NHS as the preferred destination for innovation and research under the Life Sciences vision.

There are three core components to the collaboration:

- A commercial component: the population health implementation of Inclisiran, a first-in-class siRNA LDL-C lowering therapy, into the lipid management treatment pathway for secondary prevention atherosclerotic cardiovascular disease (ASCVD) including an implementation research project in primary care,
- A clinical trial for the primary prevention of ASCVD and
- A manufacturing development consortium to improve scale-efficiency of oligonucleotides (single strands of RNA or DNA for molecular biology applications).

NICE guidance

On 1 September 2021, NICE published its Final Appraisal Document (FAD)¹ for Inclisiran which states:

1. Inclisiran is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if there is a history of any of the following cardiovascular events:
 - acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
 - coronary or other arterial revascularisation procedures
 - coronary heart disease
 - ischaemic stroke or
 - peripheral arterial disease, and
2. Inclisiran is recommended only in research for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults who have no history of cardiovascular events. This research is in the form of a clinical trial currently in development.

The FAD signalled the launch of the implementation programme to enable access to Inclisiran for eligible patients in England (where within 30-days of the publication of the NICE FAD Routine funding of Inclisiran was available).

1 National Institute for Health and Care Excellence. Final appraisal document. Available at <https://www.nice.org.uk/guidance/gid-ta10703/documents/final-appraisal-determination-document>



Guidance to support implementation of Inclisiran within the lipid management pathway



Yorkshire and Humber population eligibility

Based on the NICE submission for Inclisiran, there are approximately four million patients with ASCVD in England and the likely size of the population that will benefit from Inclisiran treatment is estimated at around 300,000 by March 2024.

The Yorkshire and Humber region has the largest CVD prevalent population in the whole of England. Within the Yorkshire and Humber region, we estimate there could be up to 65,000 people who could benefit from optimised prescribing from within general practice between now and March 2024:

This can be broken down per 100,000 CVD patients as follows:

- 1,400 per 100,000 CVD patients by March 2022
- 6,500 per 100,000 CVD patients by March 2023
- 9,200 per 100,000 CVD patients by March 2024



Communications

On 22 September 2021, NHS systems were issued with an [NHS Medicines Optimisation pack](#) for Inclisiran and accompanying [letter](#) from NHS England and NHS Improvement.

Safety and reporting

The safety and efficacy of Inclisiran were investigated in three Phase III trials, ORION-10, ORION-11 and ORION-9 on 3,457 patients.

According to the Summary of Product Characteristics, although in vitro studies were not carried out, Inclisiran is not anticipated to be a substrate for Cytochrome P450. It is not an inducer or inhibitor of P450 enzymes therefore is not expected to have clinically significant interactions with other medicinal products. For full safety information see ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_en.pdf

As with all new medicines, reporting suspected adverse reactions is important as it allows continued monitoring of the benefit/risk balance. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk



Guidance to support implementation of Inclisiran within the lipid management pathway



Funding and cost

- The NHS will fund Inclisiran centrally from a national NHS budget.
- Inclisiran will be available in primary care as a personally administered item via an FP34D form or on an FP10 prescription and will be listed in the Drug Tariff at a reimbursed price of £55 per injection.
- Inclisiran will be available from the wholesaler (AAH) at £45, which is payable 30 days from the end of that month. Inclisiran is listed in the Drug Tariff as a “zero discount” item (no clawback applicable).
- To enable primary care providers to be able to purchase Inclisiran directly from the national wholesaler for the medicine, a ‘nominal’ price (charge) has been agreed at which local primary care providers will be able to purchase the medicine. The cost to the Clinical Commissioning Group and primary care prescribing budget will be the Drug Tariff price. As the Drug Tariff price is set at a nominal price, a separate payment will be made to Novartis from a central NHS budget for the difference between the commercial agreement price and the drug tariff price.

Prescribing

To positively impact a nation’s cardiovascular health outcomes, the initiation and management of this treatment will be predominantly carried out within a primary care setting.

After an initial dose and another at three months, Inclisiran is maintained by two doses a year by subcutaneous injection.

The cost of this in primary care as mentioned above will be predominantly funded by NHS England and NHS Improvement, based on prescribing data, to facilitate and support proactive prescribing.

Secondary care is not eligible for the nominal price available in primary care and would incur a drug higher tariff.



Key players in the local healthcare partnership approach

All 15 Academic Health Science Networks (AHSNs) across the country are completing a 3-year national lipid management programme with the aim of improving patient care and outcomes by effectively treating patients with hypercholesterolaemia. Integrated Care Systems (ICSs) are positioned to set the PHM strategy and to take forward aspirations for better CVD prevention. ICSs will be accountable for the overall performance of their system in relation to the CVDPREVENT programme.

Integrated Care Systems have a responsibility to develop Primary Care Networks (PCNs) and commission primary care. PCNs will enable greater provision of proactive, personalised, and integrated health and social care.

Primary Care Networks have an opportunity to bring general practices together to work at scale. Clinical leadership is important to support the need for a Population Health Management approach to the implementation of Inclisiran. Local specialists will be relied on to provide advice and expertise. Specialists will be directly involved in the care of complex patients.

Guidance to support implementation of Inclisiran within the lipid management pathway



Next steps

In line with the NHS Medicines Optimisation Pack, local area prescribing committees are encouraged to review and adopt Inclisiran, proceed with local formulary listing and allocation of funding to GP prescribing budgets.

We are keen to support with policy interpretation and implementation and will work with you to understand the landscape locally. We have a dedicated team who are available to support further discussions, understand any challenges or barriers and identify areas for targeted local support. We are also keen to identify early adopters of Inclisiran and showcase best practice when available.

Please contact your Yorkshire & Humber AHSN Inclisiran lead Adele.bunch@yhahsn.com for more information and to begin conversations.

Available and upcoming resources

- An updated lipid-management pathway is expected imminently
- NHS Digital is developing a case finding tool/business rule set for integration into GP systems, e.g., EMIS. This aims to be live in November and will create 'in-session alerts' to support patient identification for secondary prevention of ASCVD at GP practice level. Early discussions suggest this will incorporate the NICE approved clinical pathway, a complementary asset within the AHSN Network Lipid Optimisation and FH programme
- The Accelerated Access Collaborative (AAC) is developing a Population Health Management tool, expected in November
- Tacking Cholesterol Together provides a suite of tools and resources for healthcare professionals to support the diagnoses and treatment of cholesterol patients
- The AAC and Health Innovation Manchester AHSN continues to run a series of "Town Hall events" covering Lipid-management which can be registered for and the recordings viewed at healthinnovationmanchester.com/resources-aac-lipid-management
- Cholesterol Now campaign

